Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories
-
Exact Sciences (EXAS) PT Raised to $95 at Canaccord Genuity
-
Canaccord Genuity Reiterates Buy Rating on Exact Sciences (EXAS)
-
Canaccord Genuity Reiterates Buy Rating on Exact Sciences (EXAS)
-
Exact Sciences (EXAS) PT Lowered to $85 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $115 at Canaccord Genuity
-
Natera's (NTRA) Signatera Highlighted at Liquid Biopsy Online - Canaccord Genuity
-
Exact Sciences to participate in August investor conference
-
Exact Sciences to participate in August investor conference
-
Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal
-
Exact Sciences (EXAS) PT Raised to $125 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $118 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $87 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $65 at Canaccord Genuity
-
Exact Sciences to participate in Canaccord Genuity Growth Conference
-
Exact Sciences (EXAS) PT Raised to Street High $75 at Canaccord, 'Strong execution in a robust bull market'
-
Exact Sciences (EXAS) PT Raised to $70 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $68 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $60 at Canaccord Genuity
-
Buy Exact Sciences (EXAS) on Weakness - Canaccord Genuity
-
Exact Sciences (EXAS) PT Lowered to $55 at Canaccord Genuity
-
Exact Sciences (EXAS) Selloff 'Overblown' Says Canaccord, 'We Would Aggressively Buy'
-
Exact Sciences (EXAS) PT Raised to $60 at Canaccord Genuity
-
Exact Sciences to participate in Canaccord Genuity Growth Conference
-
Exact Sciences (EXAS) PT Raised to $45 at Canaccord Genuity Following 2Q
-
Exact Sciences (EXAS): Raising PT Ahead of Earnings - Canaccord
-
Exact Sciences (EXAS) PT Lowered to $38 at Canaccord Genuity After Selling 7M Shares
-
Pre-Open Stock Movers 06/07: (DRWI) (CVNA) (SVRA) Higher; (DLTH) (ALOG) (AMBA) Lower (more...)
-
Pre-Open Stock Movers 05/31: (DAC) (JILL) (ETRM) Higher; (GEMP) (AKTX) (KORS) Lower (more...)
-
Exact Sciences (EXAS) PT Raised to $40 at Canaccord Genuity; 'UNH Adds Cologuard to Commercial Coverage'
-
Canaccord Genuity Disagrees with Citron Report on Exact Sciences (EXAS)
-
Exact Sciences to participate in November investor conferences
-
Exact Sciences to participate in Canaccord Genuity 36th Annual Growth Conference
-
Pre-Open Stock Movers 07/28: (GRPN) (N) (ALR) (FB) Higher; (INFN) (ARGS) (RCII) (F) Lower (more...)
-
Exact Sciences Announces Upsizing and Pricing of Public Offering of Common Stock
-
After-Hours Stock Movers 07/27: (PCMI) (GRPN) (CRUS) (FB) Higher; (INFN) (ARGS) (RCII) Lower (more...)
-
Exact Sciences (EXAS) Falls 4% on Plans to Sell 7M Common Shares
-
Exact Sciences Announces Agreement to Sell 7,000,000 Common Shares
-
Pre-Open Stock Movers 06/16: (PTX) (QLGC) (EXAS) Higher; (TNXP) (CAVM) (EVHC) Lower (more...)
-
Highlights from Exact Sciences (EXAS) Analyst Lunch - Canaccord
-
Exact Sciences to Participate in November Investor Conferences
-
Notable Analyst Rating Changes 10/21: (COH) (WM) (EXAS) Upgraded; (TWTR) (MU) (IAG) Downgraded
-
Canaccord Genuity Reiterates Buy on Exact Sciences (EXAS) Following USPSTF's Draft Recommendation for Colorectal Screening Guidelines
-
Canaccord Genuity Cuts Price Target on Exact Sciences (EXAS) Following Growth Conference
-
Exact Sciences to Participate in August Conferences
-
Canaccord Genuity Raises Price Target on Exact Sciences (EXAS) Ahead of Analyst Day
-
Canaccord Genuity Sees 'Significant Short Squeeze' in Exact Sciences (EXAS) Given CMS Pricing
-
Exact Sciences Corp (EXAS) Prices 10M Offering at $12.75/Share
-
Exact Sciences (EXAS) to Offering $125M Shares
-
Exact Sciences (EXAS) Prices 5.5M Shares at $12.35/Sh
-
Canaccord Genuity maintains a 'Buy' on Exact Sciences (EXAS); Q2 Preview: Unique Opportunity Presented

